ISSN 2564-7784 | E-ISSN 2564-7040
Use of botulinum toxin in urology: a literature review
1 Department of Urology, Gaziantep University School of Medicine, Gaziantep, Turkey  
2 Department of Urology, Marmara University School of Medicine, İstanbul, Turkey  
3 Department of Urology, Vanderbilt University Medical Center, Nashville, USA  
Eur J Ther 2017; 23: 131-137
DOI: 10.5152/EurJTher.2017.163
Key Words: Botulinum toxin, neurogenic detrusor overactivity, overactive bladder, detrusor sphincter dyssynergia, benign prostatic enlargement, interstitial cystitis

Botulinum neurotoxin (BoNT) is currently preferred as a minimally invasive treatment for lower urinary tract pathologies. Although BoNT injections have become widespread globally for the past 5 years, today, the urological use of BoNT Type A (BoNT-A) is only licensed for the treatment of neurogenic detrusor overactivity and overactive bladder. Despite the relative evidence for the use of BoNT-A in benign prostatic enlargement, there is no high-level evidence data for the use in detrusor sphincter dyssynergia, interstitial cystitis/bladder pain syndrome, and chronic pelvic pain. In this comprehensive review, we mention the mechanism of action and efficacy of BoNT in various urological disorders, present the reliability, and evaluate the literature data supporting its use.


How to cite: Bayrak Ö, Seçkiner İ, Onur R, Dmochowski RR. Use of Botulinum Toxin in Urology: A Literature Review. Eur J Ther 2017; 23: 131-7.

Key Words
AVES | Copyright © 2018 European Journal of Therapeutics | Latest Update: 13.12.2018